Stocks of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) traded higher last session on Wall Street, up 0.49% to $6.10.
RXRX stock price is now -18.88% away from the 50-day moving average and -32.81% away from the 200-day moving average. The market capitalization of the company currently stands at $1.72B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $8, Morgan Stanley recently initiated with Equal-Weight rating for Recursion Pharmaceuticals Inc (NASDAQ: RXRX). On March 16, 2023, Needham recently initiated its ‘Buy’ rating on the stock quoting a target price of $17, while ‘KeyBanc Capital Markets’ rates the stock as ‘Overweight’
In other news, Gibson Christopher, Officer bought 20,000 shares of the company’s stock on Sep 04 ’24. The stock was bought for $120,800 at an average price of $6.04. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 29 ’24, President and COO Marriott Tina sold 6,000 shares of the business’s stock. A total of $45,376 was realized by selling the stock at an average price of $7.56. This leaves the insider owning 521,138 shares of the company worth $3.18 million. A total of 23.67% of the company’s stock is owned by insiders.
During the past 12 months, Recursion Pharmaceuticals Inc has had a low of $4.97 and a high of $15.74. As of last week, the company has a debt-to-equity ratio of 0.15, a current ratio of 6.07, and a quick ratio of 6.07. The fifty day moving average price for RXRX is $7.5199 and a two-hundred day moving average price translates $9.07845 for the stock.
The latest earnings results from Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was released for 2024-06-30. The net profit margin was -755.37% and return on equity was -71.18% for RXRX. The company reported revenue of $14.42 million for the quarter, compared to $11.02 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 30.86 percent. For the current quarter, analysts expect RXRX to generate $30.07M in revenue.
